RELMADA THERAPEUTICS, INC.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics across three primary programs. The company's lead candidate, NDV-01, is a controlled-release intravesical formulation combining gemcitabine and docetaxel currently in Phase 2 trials for aggressive non-muscle invasive bladder cancer. Sepranolone, a neurosteroid in Phase 2b development, targets conditions associated with excessive GABAergic activity, including Prader-Willi Syndrome, Tourette Syndrome, and excessive tremor. A third program, REL-P11, is a modified-release formulation of psilocybin that completed Phase 1 safety evaluation for metabolic disease treatment.

The company operates as a pre-revenue, development-stage entity with no established revenue streams from marketed products. Relmada maintains a lean operational structure with 17 full-time employees and is headquartered in Coral Gables, Florida. The company is incorporated in Nevada and trades on Nasdaq with a market capitalization of approximately $0.3 billion as of the reporting date.